Table 5.
Summary of FDA-approved KIT-targeted therapies.
| Drug | Primary Targets | FDA-Approved Disease |
|---|---|---|
| Imatinib | BCR-ABL1 | CML, Ph+ALL, HES, GIST, SM, DFSP |
| Dasatinib | BCR-ABL1 | CML, PhALL |
| Sunitinib | VEGFR and FLT3 | GIST, RCC, Pancreatic Cancer |
| Regorafenib | VEGFR | GIST, HCC, Colorectal Cancer |
| Midostaurin | FLT3 | AML (FLT3 mutation), SM |
| Ripretinib | KIT | GIST |
| Avapritinib | KIT/PDGFRA | GIST, SM |
Abbreviations: FDA: US Food and Drug Administration, CML: chronic myeloid leukemia, PhALL: Philadelphia-positive acute lymphoblastic leukemia, HES: chronic eosinophilic leukemia with PDGFRα rearrangement, GIST: gastrointestinal stromal tumor, SM: systemic mastocytosis, DFSP: dermatofibrosarcoma protuberans, RCC: renal cell carcinoma, HCC: hepatocellular carcinoma.